[Current treatment strategy in malignant pleural effusion].
Malignant pleural effusions are a grave consequence of advanced cancer disease. The successful suppression of pleural fluid reaccumulation can make a major contribution to the management and palliative care of patients with disseminated cancer. Many treatment concepts have been reported in the literature. The recommended therapy in malignant pleural effusions consists of intrapleural instillation of a sclerotic agent to produce pleurodesis. Different substances have been used, including tetracyclines, cytostatic agents, fibrin, talc, Corynebacterium parvum, cytokines and others. We reviewed the most frequently used techniques of pleurodesis in order to define the most effective treatment concept. In 15 prospective randomized trials the success rates varied from 13% with bleomycin to 100% with talc or Corynebacterium parvum. Talc was superior to other agents in 6 of 6, Corynebacterium parvum in 3 of 4 and bleomycin or tetracycline only in 3 of 8 studies. Adverse effects were frequently observed with cytostatic agents, but were very rare in the case of talc or fibrin instillation. Comparing the recently published data pleurodesis with talc appears to be the most effective treatment strategy, followed by Corynebacterium parvum, bleomycin and tetracycline.
Türler
A
A
Allgemeine, Abdominal-, Thorax- und Gefässchirurgie, Klinik und Poliklinik für Chirurgie der Universität zu Köln, Bundesrepublik Deutschland.
Walter
M
M
Schmitz-Rixen
T
T
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage; D006801:Humans; D010166:Palliative Care; D016066:Pleural Effusion, Malignant / Q000209:etiology / Q000628:therapy*; D018700:Pleurodesis / Q000379:methods*; D011425:Propionibacterium acnes; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D013627:Talc; D013754:Tetracyclines / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D012597:Sclerosing Solutions; D013754:Tetracyclines; D001761:Bleomycin; D013627:Talc
Aktuelle Behandlungsstrategie bei malignen Pleuraergüssen.